Pegasys Growth Strategy Will Focus On HIV/HCV Co-Infection And Hepatitis B
This article was originally published in The Pink Sheet Daily
Executive SummaryRoche's pegylated interferon product has captured 52% of total Rxs. APRICOT study in HIV/HCV co-infection shows Pegasys/Copegus (ribavirin) combo therapy yields 40% sustained virologic response.
You may also be interested in...
Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.